Adial Pharmaceuticals narrows 2025 loss, clears regulatory hurdles for AD04
Adial Pharmaceuticals (NASDAQ:ADIL) reported a significant reduction in annual net losses for 2025, as the clinical-stage biotech firm secures FDA alignment and strategic partnerships to transition its lead alcohol-use disorder candidate into Phase 3 trials.

_1355135_640x360_2490907203618-640x360.jpg&w=1200&q=75)



-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)













